NOTCH1 and acute lymphoblastic leukemia: Because selective inhibitors of nuclear export do not require a mutated target and were shown to inhibit the growth of all subtypes of ALL, combination of KPT-8602 and MRK-560 could potentially benefit all T-ALL patients with activated NOTCH1 signaling.